Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Contribution of Joseph B. Kadane. Joint Statistical Meetings Miami, FL August, 2011
2. There’s Adaptive, but then There’s Really Adaptive! The Past, Present, and Future of Innovative Designs in Clinical Trials Design of Experiments in Healthcare Isaac Newton Institute for Mathematical Sciences Cambridge University Cambridge, England August, 2011
3. A Reality Check: Early Detection Sixth Era of Hope Conference Orlando, FL August, 2011
4. Using biomarkers prospectively in adaptive trials Worldwide Innovative Network in Personalized Paris, France July, 2011
5. Adaptive Clinical Trials Grand Rounds, University of Cincinnati, College of Medicine Cincinnati OH June, 2011
6. Workshop on Facilitating Collaborations to Develop Combination Investigational Cancer Therapies Institute of Medicine Washington, DC June, 2011
7. Lung Cancer Clinical Trial Design: Targeted Agents & Enriched Patient Subgroups National Lung Cancer Partnership Chicago IL June, 2011
8. Adaptive Clinical Trials in Cancer Research Sarcoma Alliance for Research through Collaboration Chicago, IL June, 2011
9. Adaptive Clinical Trials Grand Rounds, Medical Oncology and Hematology Grand Rounds, Columbia University New York, NY June, 2011
10. Adaptive Study Designs in Emergency Pandemic Research Colloquium on Pandemic Research Preparedness Toronto, Canada June, 2011
11. Are there better ways to analyze clinical trial data Alzheimer’s Association Research Roundtable Washington, DC June, 2011
12. Development of Drugs for Personalized Medicine FDA, AACR, ASCO, NCI, Duke Workshop on Accelerating Anticancer Agent Development and Validation Washingon, DC May, 2011
13. Personalized Medicine in Clinical Trials Case Comprehensive Cancer Center Cleveland, OH May, 2011
14. Adaptive Designs in Drug Development SAS Health Leader Symposium May, 2011
15. Designing Informative Clinical Trials for Personalized Medicine. Personalized Medicine: Principles to Practice A Symposium of Nature Reviews Drug Discovery, Nature Medicine and the Association of Clinical Pharmacology and Therapeutics Dallas, TX March, 2011
16. Adaptive Clinical Trials in Oncology: A Necessary Step Twenty-Second Annual Cancer Progress Conference Communitech New York City, NY March, 2011
17. Adaptive Designs for Time-to-event Clinical Trials. 9th Annual ASA Connecticut Chapter Conference on Analysis of Time-to-event Data Danbury, CT March, 2011
18. Keynote Address. Innovative and Efficient Drug Development: Endpoints, Biomarkers, Imaging, and Adaptive Designs Strategies for Clinical Oncology Drug Development, Cambridge Health Institute San Francisco, CA February, 2011
19. I-SPY2 Overview and Creative Clinical Trial Design Ruesch Scientific Symposium on Personalized Medicine and the Cure for Cancer Georgetown University, Washington, DC November, 2010
20. Examining Different Statistics-based Approaches to Clinical Trial Design Pre-phase III: Which Are Best in Oncology and How to Choose Phacilitate Oncology Forum Boston, MA November, 2010
21. Bayesian Adaptive Approaches to Proof of Concept. Cambridge Healthtech Institute’s Accelerating Proof-of-Concept meeting Philadelphia, PA October, 2010
22. Adaptive Clinical Trials: A New Paradigm in Drug Development Interesting Times: The Academic Contribution to Drug Development in an Era of Reform Institute for Translational Medicine and Therapeutics University of Pennsylvania, Philadelphia, PA October, 2010
23. Building Efficient, Informative, Biomarker-Based Clinical Trials Policy Roundtable of the National Coalition for Cancer Survivorship Washington, DC October, 2010
24. Statistical Evidence Regarding the Benefits and Limits of Screening Mammography. American College of Surgeons' 96th Annual Clinical Congress Washington, DC October, 2010
25. Statistical Perspective on Clinical Trial Design: Small ‘n’ Trials FDA, NIH, AAP, & ACC Workshop on Optimizing Clinical Trial Design for Pediatric Cardiovascular Devices San Francisco, CA September, 2010
26. Adaptive Factorial Designs for Combination Therapy in Oncology Joint Statistical Meetings Vancouver, BC, Canada August, 2010
27. Adaptive Biomarker-driven Clinical Trials The Twenty-fifth Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy 2010 Aspen CO July, 2010
28. Innovative Clinical Trials in Neurological Oncology ASCO June, 2010
29. How to Design Innovative Trials for Targeted Agents IMPAKT IMProving CAre and Knowledge through Translational Research 2010 Breast Cancer Conference Brussels, Belgium May, 2010
30. Neoadjuvant statistical designs 2010 Annual Meeting of BIG-NABCG (Breast International Group and North American Breast Cancer Group) Brussels, Belgium May, 2010
31. Adaptive Designs and Personalized Medicine in Clinical Trials Biomedical Research Centres (BRC) of UK National Institute of Health Research, London, England May, 2010
32. Adaptive Clinical Trials in Cancer Research: Focus on the I-SPY2 Trial. American Association for Cancer Research Washington, DC April, 2010
33. Innovative Clinical Trial Design in Early Drug Development 23d International Symposium on Cancer Tokyo, Japan April, 2010
34. Bayesian Approaches to Comparative Effectiveness Research Workshop on Statistical Issues in Comparative Effectiveness Research University of Pennsylvania Philadelphia PA April, 2010
35. Statistical Issues in Breast Cancer Research Donna J Brogan Annual Lecture at Emory University, Atlanta, Georgia April, 2010
36. Statistics in 2025 Eastern North American Region of the International Biometric Society New Orleans, LA March, 2010
37. (1) The Screening Mammography Brouhahas and (2) Adaptive Clinical Trials Dana-Farber Cancer Institute/Frontier Science and Technology Research Foundation Annual Lecture on Biostatistics in Cancer Sponsored by the Friends of DFCI, Cambridge, MA March, 2010
38. Decision Analysis in Clinical Research Berger Conference in Statistics San Antonio, TX March, 2010
39. Bayesian Clinical Trials for Orphan Products FDA Workshop on Orphan Drugs February, 2010
40. Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer San Antonio Breast Cancer Symposium (Joint with M Goetz and T Klein, presented by M Goetz) San Antonio, TX December, 2009
41. Small Trials for Small Patients. FDA Workshop on Pediatric Clinical Trials Washington, DC October, 2009
42. Innovative Clinical Trial Designs 60th Anniversary Celebration of Department of Biostatistics at the University of North Carolina, Chapel Hill October, 2009
43. Population Breast Cancer Mortality Reductions: Screening or Treatment Canadian Breast Cancer Research Foundation: It’s About Time! Toronto, Canada October, 2009
44. Cancer Vaccine Clinical Trial Design Issues. FDA-NCI Workshop on Therapeutic Cancer Vaccines Washington, DC October, 2009
45. Adaptive Designs in Clinical Trials International Society for CNS Drug Trials and Methodology (ISCTM) San Diego, CA October, 2009
46. Bayesian Approaches to Missing Data. National Academy of Sciences Workshop in Missing Data September, 2009
47. Statistics and The New York Times (Joint with Gina Kolata) Joint Statistical Meetings Washington, DC August, 2009
48. Discussion of Developmental Therapeutics: Cytotoxic Chemotherapy American Society of Clinical Oncology Orlando, FL June, 2009
49. Use and Interpretation of Bayesian Methods in Design and Analysis of Clinical Trials. Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) at the Centers for Medicare & Medicaid Services (CMS): Bayesian vs frequentist statistics: Applying these approaches to coverage decisions Baltimore, MD June, 2009
50. Bayesian Statistics in Medical Device Clinical Trials AdvaMed/FDA Conference on Statistical Issues for Medical Devices and Diagnostics Washington, DC April, 2009
51. Keynote Address: Clinical Trials and Biomarkers in Improving Outcomes: Focus on Breast Cancer Joint Workshop of Cancer Intervention and Surveillance Modeling Network and Integrative Cancer Biology Program Washington, DC March, 2009
52. High- vs Standard-Dose Chemotherapy with Stem Cell Support in Breast Cancer: Metaanalyses of 15 Adjuvant Trials and 6 Metastatic Trials Annual Meeting of The European Group for Blood and Marrow Transplantation Goteborg, Sweden March, 2009
53. Clinical Research Using Biomarkers NCI Latin American Breast Cancer Pilot Project Washington, DC March, 2009
54. Adaptive Trial Designs to Facilitate Identifying Effective Therapies and Their Associated Predictive Markers The Breast Cancer Intergroup of North America Correlative Science Summit Washington, DC February, 2009
55. Bayesian Biostatistics Opening address at Bayesian Biostatistics 2009 Houston, TX January, 2009
56. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials (Joint with NT Ueno, MM Johnson, X Lei, D Smith, J Caputo, L Yancey, M Bregni, T Demirer) San Antonio Breast Cancer Symposium San Antonio, TX December, 2008
57. Keynote Address: New Developments in Bayesian Clinical Trials Biopharmaceutical Applied Statistics Symposium (BASS) XV Savannah GA November, 2008
58. Adaptive Trials for Phase II and III Studies in Oncology Phacilitate Oncology Leaders' Forum San Diego CA October, 2008
59. Adaptive Phase II Trials EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland October, 2008
60. SLC Consensus on Research Priorities in Genomics Stakeholder Scientific Leadership Council in Breast Cancer Dallas TX September, 2008
61. Modeling Outcomes of Cancer Therapy Brookings Conference on Clinical Cancer Research Washington DC September, 2008
62. Molecular Marker Driven Trial Design Third Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development Philadelphia PA September, 2008
63. Building Cancer Risk Models Using Multifarious Complex Data Sources: Exploiting the Elegance of Bayes Joint Statistical Meetings Denver CO August, 2008
64. Adaptive Clinical Trial Design Era of Hope, sponsored by the US Department of Defense Baltimore MD June, 2008
65. Discussion of “Prediction of Survival Benefits from Progression-free Survival in Patients with Advanced Non-small Cell Lung Cancer: Evidence from a Pooled Analysis of 2,838 Patients Randomized in 7 trials,” by Marc E Buyse. American Society of Clinical Oncology Meeting Chicago IL June, 2008
66. Combining Lung Cancer Screening Trials Harvard/Schering-Plough Workshop in Biostatistics Cambridge MA May, 2008
67. Adaptive Trial Designs: Past, Present, and Future Third Annual Developmental Therapeutics Symposium New York Cancer Consortium New York NY May, 2008
68. Statistical Science & Decision-making University of Pennsylvania Annual Conference on Statistical Issues in Clinical Trials: From Bench to Bedside to Community Philadelphia, PA April, 2008
69. So What’s New in Breast Cancer Annual Conference of the National Breast Cancer Coalition Washington, DC April, 2008
70. Data Safety Monitoring Boards Ethics and Compliance in Oncology Research (ECOR) Houston, TX April, 2008
71. Ethics and Clinical Trials Ethics and Compliance in Oncology Research (ECOR) Houston, TX April, 2008
72. Noninferiority Clinical Trials Eastern North American Region of the International Biometric Society Arlington, VA March, 2008
73. Biostatistics, Science, and the Public Eye Presidential Invited Address, Eastern North American Region of the International Biometric Society Arlington, VA March, 2008
74. Adaptive Design of Trials involving Cancer Stem Cells as Markers Cancer Stem Cell Workshop of the National Cancer Institute Bethesda, MD January, 2008
75. Bayesian Biostatistics Opening address at Bayesian Biostatistics 2008 Houston, TX January, 2008
76. High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Breast Cancer Trials San Antonio Breast Cancer Symposium San Antonio, TX December, 2007
77. Adaptive Clinical Trials Institute of Medicine Workshop on Improving the Quality of Cancer Clinical Trials Washington, DC October, 2007
78. Bayesian Designs NIH/NIA Methodological Issues in Randomized Clinical Trials in the Elderly 2007 Bethesda, MD September, 2007
79. Drug and Device Safety Issues: A Bayesian Perspective FDA/Industry Statistics Workshop Arlington, VA September, 2007
80. Applications of Adaptive Designs, Including Seamless Phase 2b/3 Trials Drug Development Science: A Critical Path Update American College of Clinical Pharmacology Annual Meeting San Francisco, CA September, 2007
81. Progress in Using Adaptive Designs for Clinical Trials Joint Statistical Meetings Salt Lake City, UT August, 2007
82. Bayesian Approaches Alliance for Microbicide Development Alternative Trials Meeting Arlington, VA July, 2007
83. What Are Adaptive Trial Designs and How Can They Greatly Improve Drug Development American Society of Clinical Oncology Chicago, IL June, 2007
84. Dealing with Heterogeneity and Subpopulations in Clinical Trials HIV Vaccine Trials Network May, 2007
85. Overview of Meta-analysis Methods: Advantages and Limitations The Workshop, Council for Responsible Nutrition’s Day of Science: Dietary Supplements and the Evidence-based Medicine Paradigm Washington, DC May, 2007
86. Innovative Approaches for Early Drug Development: Disease Models and Novel Trial Design Frontiers Symposium of American College of Clinical Pharmacology Baltimore, MD May, 2007
87. Adaptive Design: What’s All the Talk About Annual Conference of National Breast Cancer Coalition April, 2007
88. Breast Cancer News: What’s Behind the Headlines. Annual Conference of National Breast Cancer Coalition April, 2007
89. Recent Innovations in Oncology Clinical Trials American Association of Cancer Research Los Angeles, CA April, 2007
90. Adaptive trial designs: Bayesian approaches Global HIV Enterprise Clinical Trials Workshop: Approaches to Expediting HIV Vaccine Efficacy Evaluation New York, NY April, 2007
91. Statistical Considerations in Preoperative Clinical Trials National Cancer Institute Meeting on Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions Washington, DC March, 2007
92. Bayesian Adaptive Designs: How can a Bayesian statistical approach enhance efficiency and interpretability Conference on the Design, Analysis, & Interpretation of RCT’s in Obesity Newark, NJ December, 2006
93. A Sharp Decrease in Breast Cancer Incidence in the United States in 2003 (Presented by PM Ravdin) San Antonio Breast Cancer Symposium San Antonio, TX December, 2006
94. Lumpectomy Plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer : A Report of Further Follow-up (Presented by Hughes KS) San Antonio Breast Cancer Symposium San Antonio, TX December, 2006
95. Adaptive Designs in Drug Development PhRMA/FDA Workshop on Adaptive Design Washington, DC November, 2006
96. Efficient Designs for Lupus Clinical Trials Lupus Clinical Trials Consortium Princeton, NJ October, 2006
97. Bayesian Clinical Trials International Workshop on Statistical Methodology in Clinical R&D Drug Information Association Heidelberg, Germany October, 2006
98. Just How Flexible Can a Prospective Clinical Trial Be FDA/Industry Statistics Workshop Washington DC September, 2006
99. Decision Analysis and Clinical Trial Design Joint Statistical Meetings Seattle, WA August, 2006
100. Novel Clinical Trial Designs in Cancer Research American Society of Clinical Oncology Breast Cancer Retreat Aspen, CO August, 2006
101. Bayesian Minefields: Multiplicities Workshop of the Statistical and Applied Mathematical Sciences Institute Durham, NC July, 2006
102. Utilizing Bayesian Methods to Create Optimal Trial Designs ExLpharma Workshop on Trial Design Innovation: Administering Safer Drugs Faster with Adaptive Trials Washington, DC July, 2006
103. Innovative and Efficient Bayesian Designs for Clinical Trials Drug Information Association Philadelphia, PA June, 2006
104. Bayesian Designs in Oncology Drug Information Association Philadelphia, PA June, 2006
105. Commentary on Sarcoma Trials American Society of Clinical Oncology Atlanta, Ga June, 2006
106. Bayesian Designs for Clinical Trials Society for Clinical Trials Orlando, FL May, 2006
107. Weaknesses and Strengths of a Bayesian Approach in Clinical Research Biostatistics Presidents’ Special Invited Speaker at the Canadian Statistical Society 2006 Annual Meeting London, Ontario, Canada May, 2006
108. Bayesian Approaches to Phase II/III Clinical Trials IBC Conference in Adaptive Designs Brussels, Belgium April, 2006
109. How Should We Evaluate Adjuvant Breast Cancer Data European Breast Cancer Conference Nice, France March, 2006
110. Continuum of Clinical Drug Development International Conference on Drug Development Austin, TX February, 2006
111. Challenges in the Implementation of a New Paradigm in Oncology Development, Part I: Adaptive Study Design Pharmaceutical Education and Research Institute on Changing the Paradigm in Oncology Drug Development Washington, DC February, 2006
112. Statistical Issues in the Design, Evaluation, and Monitoring of Clinical Trials with Longitudinal and Survival Endpoints Eastern North American Region of the International Biometric Society Tampa, FL January, 2006
113. Adaptive Clinical Trials Forum on Drug Discovery, Development, and Translation Institute of Medicine Washington, DC December, 2005
114. Biomarkers and Clinical Trials Consensus Conference National Breast Cancer Coalition Philadelphia PA November, 2005
115. Bayesian Adaptive Designs for Clinical Trials IBC Conference in Implementing Adaptive Designs for Drug Development Princeton, NJ November, 2005
116. Innovative Clinical Trial Designs in Prostate Cancer Research Prostate Cancer Foundation Scientific Retreat Phoenix AZ October, 2005
117. Proof of Concept Trials in Pharmaceutical Research The Austrian-Swiss Region (ROeS) of the International Biometric Society (IBS), Graz, Austria September, 2005
118. Bayesian Trial Design: Drug Case Study FDA/Industry Biopharm Workshop Washington, DC September, 2005
119. Incorporating Biological Information in Hierarchical Modeling of Many Genetic Disease Markers and Safety Data in Drug Studies Joint Statistical Meetings Minneapolis, Minnesota August, 2005
120. Bayesian Methods in Clinical Research: Collecting and Using Information Effectively Society of Toxicology Washington, DC July, 2005
121. Clinical Trials of the Future. Era of Hope Philadelphia, PA June, 2005
122. Bayesian Approaches in Multiplicities OBayes: International Conference on Objective Bayesian Methods Branson, MO June, 2005
123. Bayesian Inference in Pharmaceutical Research Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 2005
124. Biomarkers in Clinical Trial Design: Prognosis and Prediction IBC Conference in Using Biomarkers in Clinical Research Boston, MA March, 2005
125. Clinical Trials Design Challenges Using Biomarker Stratification NCI/FDA conference: Strategies To Integrate Biomarkers Into Cancer Clinical Trials Houston, TX February, 2005
126. Adaptive Design and Combining Phases: A Bayesian Perspective Keynote presentation, IBC Conference in Adaptive Designs Boston, MA February, 2005
127. Advances in Clinical Trial Design Methodology AAMC/FDA/CDDS Conference on Drug Development Science: Obstacles and Opportunities for Academia, Industry and Government Washington, DC January, 2005
128. Proof of Concept Trials in Pharmaceutical Research Joint Statistical Meetings Minneapolis, Minnesota January, 2005
129. The Vagaries of Using Biomarkers in Early Detection of Cancer Gordon Conference on New Frontiers in Cancer Detection & Diagnosis Santa Barbara, CA January, 2005
130. Effects of Improvements in Chemotherapy on Disease-free and Overall Survival of Estrogen-receptor Negative, Node-positive Breast Cancer: 20-year Experience of the CALGB & U.S. Breast Intergroup San Antonio Breast Cancer Symposium San Antonio, TX December, 2004
131. Adaptive Trial Design: Why, When and How FDA-PhRMA-DIA Conference on Good Dose-Response—Rewards of Success, Cost of Failure: A Critical Path Opportunity to Focus on Optimizing Benefit/Risk Arlington, VA October, 2004
132. Innovations in Clinical Trial Design and Analysis Merck-Temple Conference in Biostatistics Philadelphia, PA October, 2004
133. Bayesian Adaptive Designs and Interim Analyses FDA/ASA Industry Workshop Washington, DC September, 2004
134. Adaptive Clinical Trials Joint Statistical Meetings Toronto, Canada August, 2004
135. Biomarkers in the Clinical Trial Design for Diagnosis and Early Detection Joint NCI-FDA Workshop on Research Strategies, Study Designs and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection Washington, DC July, 2004
136. Presidential Invited Address, Western North American Region of the International Biometric Society Albuquerque, NM June, 2004
137. Data & Safety Monitoring Boards and Early Release of Trial Results “Meet the Professor” American Society of Clinical Oncology New Orleans, LA June, 2004
138. Bayes at the FDA: Efficient Designs and Borrowing Strength International Society of Bayesian Analysis Viña del Mar, Chile May, 2004
139. Case Study: Spinal Implant PMA FDA/Johns Hopkins Workshop on Bayesian Approaches for Regulatory Decisions Bethesda, MD May, 2004
140. Basic Bayesian Statistics FDA/Johns Hopkins Workshop on Bayesian Approaches for Regulatory Decisions Bethesda, MD May, 2004
141. Novel Approaches to Data Analysis and Evaluation in Stroke Trials Baltimore, MD Stroke Treatment Academic Industry Roundtable April, 2004
142. Early Disclosure of Positive Results of Randomised Trials 4th European Breast Cancer Conference Hamburg, Germany March, 2004
143. The Future of Biostatistical Science Eastern North American Region of the International Biometric Society Pittsburgh, PA March, 2004
144. You Want to Publish, Get Your Statistics Right 4th European Breast Cancer Conference Hamburg, Germany March, 2004
145. Adaptive Designs for Cancer Clinical Trials National Coalition for Cancer Survivorship Industry Roundtable Washington, DC November, 2003
146. Decision Analysis in Clinical Trials Society of Medical Decision Making Chicago, IL October, 2003
147. Three-level Hierarchical Modeling of Drug Safety Data Drug Information Association Biostatistics Workshop Hilton Head, SC March, 2003
148. Statistical Issues in the Screening Mammography Controversy Eastern North American Region of the International Biometric Society Tampa, FL March, 2003
149. New AJCC Breast Cancer Staging Systems Trends in Breast Cancer Boston, MA February, 2003
150. Risk Trade-offs in Making Decisions about Cancer American Association of Cancer Research Boston, MA October, 2002
151. The Promise and Reality of Biomarkers: Hopeful but Cautionary Tales An Era of Hope in Breast Cancer, sponsored by the US Department of Defense Orlando, FL September, 2002
152. The Benefits and Risks of Screening Mammography Mayo Clinic Medicine and Media Conference Rochester, MN September, 2002
153. Keynote Address on Cancer Prevention, Control and Epidemiology Cancer Symposium of the University of California Sacramento, CA September, 2002
154. Bayesian Approaches to Safety Analyses Joint Statistical Meetings New York, NY August, 2002
155. Do Mammograms Save Lives The Future of Breast Cancer: An International Breast Cancer Congress Bahamas July, 2002
156. Bayesian Adaptive Designs Drug Information Association Chicago IL June, 2002
157. Statistical Considerations for Using Biomarkers: In the Clinic & Clinical Trials NCI-EORTC Conference in Tumor Markers Washington, DC June, 2002
158. Assessing the Benefits and Risks of Mammographic Screening Global Summit on Mammographic Screening Milan, Italy June, 2002
159. Adaptive Randomization in Clinical Trials: Learning while Delivering Better Treatment Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 2002
160. Bayesian Adaptive Designs and Monitoring Schemes Schering-Plough/Harvard Workshop on Emerging Strategies in Designing and Monitoring Clinical Trials Cambridge, MA May, 2002
161. The Screening Mammography Controversy: Science, Politics and the Press . . . and Women in the Middle Conference of Texas Statisticians Houston, TX April, 2002
162. Decision Analysis in the Pharmaceutical Industry Eastern North American Region of the International Biometric Society Washington, DC Mar March, 2002
163. Innovations in Clinical Trial Design American Society of Experimental Neurotherapeutics Washington, DC March, 2002
164. Bayesian Statistics and Decision Analysis in Medical Research First Latin American Bayesian Congress and International Society of Bayesian Analysis Ubatuba, Sao Paulo, Brazil February, 2002
165. Novel Clinical Trial Design and Implementation M D Anderson Clinical Conference Houston TX January, 2002
166. Innovations in Clinical Trial Design and Drug Development Strategies National Academy of Sciences, Institute of Medicine Washington, DC October, 2001
167. Medical Device Development: Taking a Bayesian Perspective Society for Clinical Trials Denver, CO May, 2001
168. Role of Clinical Trials in Breast Cancer Research and Treatment Helene Harris Memorial Trust, 8th Biennial International Forum on Ovarian Cancer Houston, TX March, 2001
169. Innovative Bayesian Designs in Clinical Trials Foundations of Statistical Inference: Applications in Medicine, Social Sciences, and Industry, and the Interface with Computer Science Jerusalem, Israe December, 2000
170. Statistical Modeling of Genetics and Screening in Breast Cancer Cancer Genetics Network Workshop Houston, TX November, 2000
171. Using the Bayesian Approach in Phase II and III Clinical Trials American Association of Pharmaceutical Sciences Indianapolis, IN October, 2000
172. Innovative Bayesian Designs in Clinical Trials. US Army Conference in Applied Statistics Rice University, Houston, TX October, 2000
173. Using the Bayesian Approach in Medical Research and Clinical Trials Bayesian Workshop of National Institute of Environmental Health Services Washington, DC September, 2000
174. Using a Bayesian Approach in Drug and Medical Device Development Joint Statistical Meetings Indianapolis, IN August, 2000
175. Recent Developments on the Bayesian Biostatistics Front Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 2000
176. Predictive Probabilities and Data Safety Monitoring Boards Duke Clinical Research Institute IRB Think-Tank Conference Durham, NC May, 2000
177. Adaptive Designs for Dose Finding and Drug Development American Society for Clinical Pharmacology and Therapeutics Los Angeles, CA March, 2000
178. Politics and the Conduct and Interpretation of Clinical Trials: Mammography Screening for Women in Their 40s Eastern North American Region of the International Biometric Society Chicago, IL March, 2000
179. When Should They Be Repeated Conference on Ethical and Value Issues in Clinical Trials Birmingham AL February, 2000
180. Recent Innovations in Clinical Trials International Conference on Medical Statistics Oberwolfach, Germany February, 2000
181. Bayesian Designs for Pharmaceutical Studies Henry Stewart Conference on Mathematical and Statistical Techniques in Clinical Trials Washington November, 1999
182. Using Bayesian Methods in Clinical Trials Biotechnology 99: Medical Applications of Biotechnology Havana, Cuba November, 1999
183. Using Surrogate Endpoints in Clinical Trials Henry Stewart Conference on Understanding, Applying and Not Misusing the Statistical Techniques Used in Clinical Trials Washington, DC November, 1999
184. Using Bayesian Methods to Put Efficacy and Safety Data in Perspective PhRMA Bethesda, MD November, 1999
185. Relevance of HER-2/neu Expression for Chemotherapy in Breast Cancer National Cancer Institute Symposium on HER-2/neu Washington, DC October, 1999
186. Using Bayesian Methods in Drug and Medical Device Development Foundational Issues and Their Practical Impact on Survey Sampling and Medical Statistics Bibbiena, Italy October, 1999
187. Bayesian Designs for Dose-Ranging Drug Trials Case Studies in Bayesian Statistics Workshop V Pittsburgh, PA September, 1999
188. Quantifying Evidence in Clinical Trials: A Bayesian Perspective Joint Statistical Meetings Baltimore, MD August, 1999
189. Bayesian Approaches to Sample Size Determination Joint Statistical Meetings Baltimore, MD August, 1999
190. The Bayesian Approach in the Design of Clinical Trials Drug Information Association Tokyo, Japan August, 1999
191. Bayesian Designs for Clinical Trials. Schering-Plough/Harvard Workshop on Bayesian Inference in Clinical Trials Schering-Plough/Harvard Workshop on Bayesian Inference in Clinical Trials Cambridge, MA June, 1999
192. Sequential Methods in Clinical Trials Biostatistics section of the Statistical Society of Canada Regina, Saskatchewan, June, 1999
193. Conventional- Vs High-Dose Therapy for Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B and Blood and Marrow Transplant Registry Patients American Society of Clinical Oncology Atlanta, GA May, 1999
194. Statistical Overview of Bone Marrow Transplantation in Breast Cancer American Society for Blood and Marrow Transplantation Atlanta, GA May, 1999
195. Scientific Inference in Cases of Suspected Athlete Drug Abuse Duke International Conference on Doping Durham, NC May, 1999
196. Bayesian Designs for Pharmaceutical Studies. Henry Stewart Conference on Mathematical and Statistical Techniques in Clinical Trials Frankfurt, Germany April, 1999
197. Biomarkers and Surrogate Endpoints in Cancer Prevention Studies Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications US Public Health Service Washington, DC April, 1999
198. Statistical Inference and the Law Eastern North American Region of the International Biometric Society Atlanta, GA March, 1999
199. Using Surrogate Endpoints in Clinical Trials Institute of Mathematical Statistics Atlanta, GA March, 1999
200. Genetic Risk of Breast Cancer Based on Family History and Decision Making of Genetic Testing American Society of Clinical Oncology Train-the-Trainer Workshop New Orleans, LA March, 1999
201. Using Surrogate Endpoints in Clinical Trials Henry Stewart Conference on Understanding, Applying and Not Misusing the Statistical Techniques Used in Clinical Trials San Diego, CA February, 1999
202. Modeling Trial Heterogeneity and Risk/Benefit Analysis of Screening Mammography for Women in Their 40s Workshop on Methodologic Issues in the Design and Evaluation of Cancer Screening Interventions Washington, DC January, 1999
203. Using Bayesian Methods in Medical Device Development Food and Drug Administration/Health Industry Manufacturers Association Conference Rockville MD November, 1998
204. Bayesian Methods and the Future of Randomized Controlled Trials Fifty Years of Clinical Trials: Past, Present and Future British Medical Association/British Medical Journal London, UK October, 1998
205. An Overview of Bayesian Methods in Clinical Research ASA Biopharmaceutical Section of the American Statistical Association Arlington, VA September, 1998
206. Validation of BRCAPRO, Sensitivity of Sequencing BRCA1 and BRCA2, and Implications for the Existence of Other Breast Cancer Susceptibility Genes SPORE Investigators' Workshop Rockville, MD July, 1998
207. Pharmaceutical Company Decision Making and the Conduct of Clinical Trials. Drug Information Association Boston, MA June, 1998
208. Analysis of Paired Survival Data Drug Information Association Boston, MA June, 1998
209. A CALGB 3x2 Factorial Trial Examining the Use of Doxorubicin (Adriamycin) and Paclitaxel (Taxol) as Adjuvant Therapy in Breast Cancer Schering-Plough/Harvard Workshop on Monitoring Clinical Trials Cambridge, MA May, 1998
210. Ethical Issues in Clinical Trials Ethics in Clinical Trials and Implications for Biometrics Basel, Switzerland May, 1998
211. Mathematical and Statistical Techniques in Clinical Trials Rockville, MD April, 1998
212. Efficient and Ethical Designs for Clinical Trials Drug Information Association Hilton Head, SC March, 1998
213. Using Bayesian Statistics in Assessing Risks of Radiation Exposure 43rd Annual Conference on Bioassay, Analytical, and Environmental Radiochemistry (BAER), sponsored by the US Department of Energy Charleston SC November, 1997
214. Assessing the Evidence for Screening Mammography for Women in their Forties An Era of Hope in Breast Cancer, sponsored by the US Department of Defense Washington DC November, 1997
215. Breast Cancer, Genetics, and Clinical Trials Keynote address, Joint meeting: New England Regional Genetics Group and Rhode Island Commission on Women Providence RI October, 1997
216. Bayesian Statistics: Attitudes and Methods Army Applied Statistics Conference, George Mason University October, 1997
217. Bayesian Biostatistical Methods Course presentation to the Swedish Association for Medical Statistics Lund, Sweden October, 1997
218. Using a Bayesian Approach in Medical Device Development. Course presentation to the U.S Food and Drug Administration, Center for Devices and Radiological Health Washington DC September, 1997
219. Metaanalysis: Fixed vs. Random Effects Henry Stewart Conference on Doing and Understanding Meta Analysis Rockville, MD September, 1997
220. Modeling Risk of Breast Cancer and Decisions about Genetic Testing Case Studies in Bayesian Statistics Workshop IV Pittsburgh, PA September, 1997
221. Bayesian Methods in the Design and Analysis of Clinical Trials Joint Statistical Meetings Anaheim, CA August, 1997
222. Using Historical Controls, Decision Making, and Adaptive Designs in Clinical Trials Workshop on Statistics in Medicine at Institute of Mathematics and Its Applications, Minneapolis, MN July, 1997
223. Statistical and Decision Making Issues in Breast Cancer Cancer and Leukemia Group B, Montreal, Canada June, 1997
224. Synthesizing Disparate Sources of Information Spring Meetings of the Eastern North American Region of the International Biometric Society Memphis, TE March, 1997
225. Benefits and Risks of Screening Mammography Between the Ages of 40 and 49. National Breast Cancer Coalition Board New York, NY March, 1997
226. Benefits and Risks of Screening Mammography Between the Ages of 40 and 49 National Cancer Advisory Board Bethesda, MD February, 1997
227. Handling Multiple Comparisons and Other Multiplicities in Clinical Trials Henry Stewart Conference on Mathematical and Statistical Techniques in Clinical Trials Rockville, MD October, 1996
228. Teaching Introductory Bayesian Statistics with Real Applications in Science: Doing What Comes Naturally Joint Statistical Meetings Chicago, IL August, 1996
229. Bayesian Approaches to Problems with Multiplicities: Applications to Multiple Comparisons International Conference on Multiple Comparisons Tel Aviv, Israel June, 1996
230. Bayesian Biostatistics Keynote address at Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 1996
231. Flexible Designs for Clinical Trials: A Bayesian Perspective Schering-Plough/Harvard Workshop in Biostatistics Cambridge, MA May, 1996
232. Bayesian Perspective on the Design and Analysis of Clinical Trials Closing address at Harvard Symposium on Bayesian Approaches to Clinical Trials, Cambridge MA March, 1996
233. Assessing the Probability of Carrying a Breast Cancer Gene Based on Family History Third World Meeting of the International Society for Bayesian Analysis Oaxaca, Mexico September, 1995
234. Statistical Issues in Health Care Keynote address at Third Annual Great Lakes Symposium on Statistical Issues in Health Care Medicine Kalamazoo MI June, 1995
235. Prognostic Factors in High Dose Therapy American Society of Clinical Oncology Los Angeles CA May, 1995
236. Statistical Analysis and the Illusion of Objectivity Fifth International Congress on Anti-Cancer Chemotherapy Paris, France February, 1995
237. Therapeutic Significance of Biological Markers in Breast Cancer Eastern North American Region of the Biometrics Society Research Triangle Park, NC January, 1995
238. Innovative Designs for Clinical Trials Parke-Davis Distinguished-Speaker Seminar Ann Arbor, MI November, 1994
239. Scientific Inference and Predictions; Multiplicities and Convincing Stories: A Case Study in Breast Cancer Therapy Fifth International Meeting on Bayesian Statistics Valencia, Spain June, 1994
240. Bayesian Approaches to Designing and Analyzing Experiments Series of Special Invited Lectures at Taiwan Universities May, 1994
241. Designing Efficient and Informative Clinical Trials Keynote Address at Drug Information Association Biostatistics Workshop Hilton Head, SC March, 1994
242. c-erbB-2 and Doxorubicin Therapy in Node-Positive Early Breast Cancer National Cancer Institute Conference on Using New Biologic Markers in Breast Cancer Research and Therapy Washington DC November, 1993
243. Factorial Designs: Advantages and Disadvantages in Clinical Studies Cancer and Leukemia Group B Breast Cancer Scientific Session Chicago, IL November, 1993
244. Discussion of "Elicitation, Monitoring, and Analysis for an AIDS Clinical Trial" by Carlin BP, Chaloner KM, Louis TA, Rhame FS Workshop in Applied Bayesian Statistics at Carnegie Mellon University Pittsburgh, PA October, 1993
245. Commentary on DNA Fingerprinting Workshop of National Institute of Statistical Sciences Research Triangle Park, NC October, 1993
246. Adaptive Designs for Clinical Trials: An Overview Pharmaceutical Marketing Association Seattle, WA September, 1993
247. Bayesian Attitudes and Methods in Clinical Trials: From Design to Handling Multiplicities. Joint Statistical Meetings San Francisco, CA August, 1993
248. Statistical Potpourri Graduate Student Seminar Sessions in Statistics and Biostatistics Pittsburgh, PA July, 1993
249. Statistics, Statistical Reasoning and Metaanalysis Association for Practitioners of Infection Control Orlando, FL May, 1993
250. Multiplicities: Bayesian Attitudes and Methods Second Merck/Temple Conference in Biostatistics Philadelphia, PA November, 1992
251. Bayesian Metaanalysis Joint Statistical Meetings Boston, MA August, 1992
252. Adaptive Group Sequential Assignment in Clinical Trials IMS-AMS-SIAM Summer Conference in the Mathematical Sciences: Adaptive Methods South Hadley, MA July, 1992
253. Metaanalysis and Using Historical Controls in Clinical Trials Fifth Symposium on Decision Theory and Related Topics Purdue University, West Lafayette, IN June, 1992
254. Clinical Research in the Critical Care Environment First World Congress of Pediatric Intensive Care Baltimore, MD June, 1992
255. Statistical Inferences in Crime Investigations Using DNA Profiling (Presented by Evett IW) Read before the Royal Statistical Society London, UK November, 1991
256. A Case for Bayesianism in Clinical Trials Special Conference on Methodology in Clinical Trials at London School of Economics London, UK June, 1991
257. Alternative Approaches to Clinical AIDS Research US Food and Drug Administration Workshop on The Role of Alternative Data Sources in AIDS Drug Development: Optimizing the Yield from Observational Data Bases and Expanded Access Protocols through Alternative Study Designs Washington, DC May, 1991
258. Public Health Decision Making: A Sequential Vaccine Trial Fourth International Meeting on Bayesian Statistics Valencia, Spain April, 1991
259. An Alternative Approach to Drug Development "State-of-the-art" address invited by President of American Society for Clinical Pharmacology and Therapeutics San Antonio, TX March, 1991
260. Quantifying DNA-Based Identification American Association for the Advancement of Science Washington, DC February, 1991
261. A Bayesian Approach to Metaanalysis and Multicenter Trials Joint Statistical Meetings Anaheim, CA August, 1990
262. Some Bandit Problems IMS-AMS-SIAM Summer Conference in the Mathematical Sciences: Sequential Search and Selection in Real Time Amherst, MA June, 1990
263. Effective Evaluation of DNA Single-Locus Profiles in Crime Investigations International Conference on Forensic Statistics Edinburgh, UK April, 1990
264. Bayesian Analysis of Phase III Trials Drug Information Association Biostatistics Workshop Hilton Head, SC March, 1990
265. Bayesian Methods in Biostatistics Annual Conference on Applied Statistics Atlantic City, NJ December, 1989
266. Are Randomized Clinical Trials Ethical If They Withhold ECMO from Newborns with Respiratory Failure? UCLA Conference on Ethics in Clinical Trials Los Angeles October, 1989
267. Inferential Aspects of Adaptive Allocation Rules Joint Statistical Meetings Washington, DC August, 1989
268. Annual Meeting of the Society for Clinical Trials Minneapolis, MN May, 1989
269. Challenge of the Future of Statisticians in the Biopharmaceutical Field: Academic Perspective Biometric Society Meetings Lexington, KY March, 1989
270. Making Decisions in Drug Development Basel Statistics Association Basel, Switzerland September, 1988
271. Bayesian Methodology in Clinical Trials International Society of Clinical Biostatistics Innsbruck, Austria August, 1988
272. Inferences Concerning Adverse Experiences in Pharmaceutical Trials Joint Statistical Meetings New Orleans, LA August, 1988
273. Adaptive vs. Randomized Allocation in Clinical Trials Institute of Mathematical Statistics Honolulu, HI June, 1988
274. Monitoring for Safety in Randomized Clinical Trials Biometric Society Meetings Boston, MA March, 1988
275. Games, Sports, Gambling and Sex: Who Says Statistics Is Dull Keynote Address at Ohio Statistics Day Bowling Green, OH November, 1987
276. Bayes's Theorem, Independence, and the Probability of Paternity International Association of Forensic Sciences Vancouver, Canada August, 1987
277. Subjectivity in Clinical Trials Joint Statistical Meetings San Francisco, CA August, 1987
278. Multiple Comparisons, Multiple Tests, and Data Dredging: A Bayesian Perspective Third International Meeting on Bayesian Statistics Valencia, Spain June, 1987
279. Bandit Problems Mathematical Sciences Institute Workshop on Deterministic and Stochastic Control Cornell University Ithaca, NY April, 1987
280. Prophets and Bandits Mathematical Sciences Institute Workshop on Deterministic and Stochastic Control Cornell University Ithaca, NY April, 1987
281. A Bayesian Approach to Pharmaceutical Company Decision Making International Conference on Practical Bayesian Statistics Cambridge, UK July, 1986
282. Bandit Problems and Optimal Stopping International Conference on Gambling and Optimal Stopping Oberwolfach, West Germany June, 1986
283. The Relevance of Stopping Rules in Statistical Inference Fourth Symposium on Decision Theory and Related Topics Purdue University, West Lafayette, IN June, 1986
284. Marshall-MacIntosh LAD vs. Nonaugmented Controls Second Symposium on Prosthetic Augmentation of Autogenous Grafts St Paul, MN March, 1986
285. Interim Analysis and Sequential Clinical Trials: The Role of the Likelihood Principle International Conference on Foundations of Statistical Inference Tel Aviv, Israel December, 1985
286. A Converse of the Gittins-Jones Result for Bandit Problems Operations Research Society of America Atlanta, GA November, 1985
287. Some Issues in the Design of Experiments Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 1985
288. Are Clinical Trials Designed to Deliver Good Medicine? Summer Research Conference in Statistics Arkadelphia, AR June, 1984
289. Outliers and Transformations Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 1984
290. Calculating a Probability of Paternity Clarifications and Criticism Minnesota Trial Lawyers Association Minneapolis, MN December, 1983
291. One- and Two-armed Bandit Problems Midwest Statistics Colloquium Purdue University, IN October, 1983
292. Statistics of Disputed Paternity Cases Joint Statistical Meetings Toronto, Canada August, 1983
293. Classical vs. Bayesian vs. Ad Hoc Approaches to Interim and Sequential Analysis. Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 1983
294. Optimal Stopping in Bandit Problems Institute of Mathematical Statistics Nashville, TN March, 1983
295. Probability Theory. Brasov Brasov, Rumania August, 1982
296. Inferring Effect of Antiarrhythmic Drugs Midwest Biopharmaceutical Statistics Workshop Muncie, IN May, 1982
297. Bandit Problems with Random Discounting Conference on Mathematical Learning Models—Theory and Algorithms University of Bonn, West Germany May, 1982
298. Adaptive Methods in Clinical Trials American Mathematical Association June, 1979
299. Red-and-Black with Unknown Win Probability NBER-NSF Seminar on Bayesian Inference in Econometrics May, 1973



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Clinical Trial Design in the Genomic Era Co-Chairpersons: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX, and George W. Sledge, Jr., Stanford University School of Medicine, Stanford, CA AACR Annual Meetings April, 2013
SESSION 7 | STRATEGIES TO IMPROVE EFFICIENCY OF CLINICAL TRIALS 3rd WIN Symposium July, 2011
CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Scientific Committee on the design of clinical trials, data processing and access (open to the public) 3rd WIN Symposium July, 2011
Using biomarkers prospectively in adaptive trials 3rd WIN Symposium July, 2011
Adaptive Designs for Stem Cell Clinical Trials THE STEM CELL MEETING – Burrill and Compay March, 2007

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.